How to Select Therapy in Relapsed/Refractory CLL

Slides:

Advertisements

Similar presentations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advertisements

Evolving Paradigms in the Management of HR-Positive Breast Cancer

Treatment Algorithms in Melanoma: Past, Present, and Future

Applying Biosimilars in Hematologic Cancers

Unraveling Clinical Developments in NASH

Improving Survival in Glioblastoma Multiforme

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advances in Managing Inhibitors in Patients With Hemophilia A

Relapsed/Refractory Follicular Lymphoma Conundrums

Progression After Cancer Immunotherapy in Advanced NSCLC

Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.

Mid-Year Hemophilia Update

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Current and Future Goals in the Treatment of Relapsed CLL

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Nurse View.

Addressing Disease Burden in Asthma

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Treatment Decisions in Chemorefractory Follicular Lymphoma

Management Challenges in CLL

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Management of CMV in HSCT Recipients

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Navigating New Oral Treatment Algorithms in CLL

Managing Adverse Events With New Oral Therapies in CLL

Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Optimizing Outcomes and Managing Adverse Events in CLL

Immunotherapy for cSCC

CGRP Antibodies in Migraine

Personalized Therapy in Relapsed or Refractory CLL

How to Select Therapy In Newly Diagnosed CLL

Personalizing Management in the Care of Patients With Advanced Sarcoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Parkinson Disease Psychosis

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Non-Chemotherapy Combinations in CLL

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Patient Questions and Expert Answers in Psoriasis:

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

Evaluating BTK Inhibitors in CLL

Managing CLL With BTK Inhibitors

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

Tailoring Therapy in the Newly Diagnosed Patient With CLL

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Treatment Initiation and Selection in Newly Diagnosed CLL

Presentation transcript:

How to Select Therapy in Relapsed/Refractory CLL

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Survival by Increased Lines of Chemotherapy

Factors Impacting Treatment Selection

Importance of FISH Testing

Considerations for Second-Line Chemotherapy

Results With Second-Line Chemotherapy

Second-Line Chemotherapy Combinations

Ibrutinib in Relapsed/Refractory CLL – RESONATE Trial

Idelalisib Clinical Trials

Idelalisib + Rituximab in Relapsed CLL

Venetoclax in del(17p) Relapsed CLL

Managing TLS

Venetoclax + Rituximab

Adverse Events With Ibrutinib

Chimeric Antigen Receptor T Cells

How Do You Choose?

Sequencing Novel Agents

Concluding Remarks